Answers are grounded in this paper and cite their sources.
The study presented here investigates the effect of HMGB1 knockout on the sensitivity of mouse embryonic fibroblasts treated with the anticancer drug cisplatin. We evaluated both the growth inhibition by cisplatin and cisplatin-induced cell death in the Hmgb1−/− cells and its wild-type counterpart. No significant differences were observed in the responses of these cells to cisplatin, indicating that HMGB1 does not play a significant role in modulating the cellular responses to cisplatin in this context. Since HMGB1 significantly enhances the cytotoxicity of cisplatin in other cells, these results illustrate the importance of cell type in determining the ability of this and probably other cisplatin-DNA-binding proteins to influence the efficacy of the drug. The study presented here investigates the effect of HMGB1 knockout on the sensitivity of mouse embryonic fibroblasts treated with the anticancer drug cisplatin. We evaluated both the growth inhibition by cisplatin and cisplatin-induced cell death in the Hmgb1−/− cells and its wild-type counterpart. No significant differences were observed in the responses of these cells to cisplatin, indicating that HMGB1 does not play a significant role in modulating the cellular responses to cisplatin in this context. Since HMGB1 significantly enhances the cytotoxicity of cisplatin in other cells, these results illustrate the importance of cell type in determining the ability of this and probably other cisplatin-DNA-binding proteins to influence the efficacy of the drug. cis-diamminedichloroplatinum(II) high mobility group HMG box protein 1 sulforhodamine B propidium iodide fluorescein isothiocyanate FITC-conjugated annexin V cis-Diamminedichloroplatinum(II) (cisplatin)1 is one of the most widely used anticancer drugs for the treatment of a variety of human malignancies (1Jamieson E.R. Lippard S.J. Chem. Rev. 1999; 99: 2467-2498Crossref PubMed Scopus (2565) Google Scholar). Whereas cisplatin is extremely effective in treating testicular cancer, the cure rate being >90% when tumors are promptly diagnosed (2Bosl G.J. Motzer R.J. N. Engl. J. Med. 1997; 337: 242-253Crossref PubMed Scopus (757) Google Scholar), the curative potential of the drug against other tumors, such as ovarian, breast, and lung cancers, is significantly undermined by intrinsic and acquired resistance (3Perez R.P. Eur. J. Cancer. 1998; 34: 1533-1542Abstract Full Text Full Text PDF Scopus (336) Google Scholar). Determining the factors that influence cellular sensitivity to cisplatin is thus important for understanding the anticancer activity of cisplatin and for developing a more effective platinum-based chemotherapy. The cytotoxicity of cisplatin arises from its ability to react with DNA and form covalent DNA adducts (4Lepre C.A. Lippard S.J. Nucleic Acids Mol. Biol. 1990; 4: 9-38Crossref Google Scholar). The major adducts, 1,2-intrastrand d(GpG) and d(ApG) platinum-DNA cross-links, are formed by coordination of the {Pt(NH3)2}2+ moiety to the N7 atoms of adjacent purines in double-stranded DNA. The cisplatin modification produces distinct changes in the architecture of the DNA duplex that inhibit replication and transcription and stimulate nucleotide excision repair (1Jamieson E.R. Lippard S.J. Chem. Rev. 1999; 99: 2467-2498Crossref PubMed Scopus (2565) Google Scholar). Cisplatin damage throughout the genome leads to cell cycle arrest and apoptosis (5Chu G. J. Biol. Chem. 1994; 269: 787-790Abstract Full Text PDF PubMed Google Scholar). Moreover, cisplatin-DNA adducts are recognized by a variety of cellular proteins, a process that may affect the fate of platinum-DNA lesions and the responsiveness of tumor cells to cisplatin treatment (6Zlatanova J. Yaneva J. Leuba S.H. FASEB J. 1999; 12: 791-799Crossref Scopus (117) Google Scholar, 7Kartalou M. Essigmann J.M. Mutat. Res. 2001; 478: 1-21Crossref PubMed Scopus (326) Google Scholar). Recognition of cisplatin-modified DNA by damage recognition proteins in the nucleotide excision repair pathway leads to the removal of platinum lesions and restoration of genomic integrity. Studies have suggested that increase in the repair of platinum-DNA adducts is key to cisplatin resistance (3Perez R.P. Eur. J. Cancer. 1998; 34: 1533-1542Abstract Full Text Full Text PDF Scopus (336) Google Scholar). Several proteins not involved in repair, including HMGB1, TATA-binding protein, and other structure-specific recognition proteins, also bind tightly to the major platinum-DNA adducts (1Jamieson E.R. Lippard S.J. Chem. Rev. 1999; 99: 2467-2498Crossref PubMed Scopus (2565) Google Scholar). The role that these proteins might play in mediating the cytotoxicity of cisplatin is a subject of much current interest. One hypothesis, which has been proposed in various studies, suggests that the binding of these proteins to platinum-DNA adducts blocks the removal of DNA lesions, thereby enhancing the sensitivity of cells to cisplatin (8Donahue B.A. Augot M. Bellon S.F. Treiber D.K. Toney J.H. Lippard S.J. Essigmann J.M. Biochemistry. 1990; 29: 5872-5880Crossref PubMed Scopus (125) Google Scholar, 9Lippard S.J. The Robert A. Welch Foundation 37th Conference on Chemical Research. The Robert A. Welch Foundation, Dallas, TX1993: 49-60Google Scholar, 10Brown S.J. Kellett P.J. Lippard S.J. Science. 1993; 261: 603-605Crossref PubMed Scopus (180) Google Scholar, 11Huang J.-C. Zamble D.B. Reardon J.T. Lippard S.J. Sancar A. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 10394-10398Crossref PubMed Scopus (340) Google Scholar, 12McA'Nulty M.M. Whitehead J.P. Lippard S.J. Biochemistry. 1996; 35: 6089-6099Crossref PubMed Scopus (52) Google Scholar, 13McA'Nulty M.M. Lippard S.J. Mutat. Res. 1996; 362: 75-86Crossref PubMed Scopus (89) Google Scholar, 14Zamble D.B., Mu, D. Reardon J.T. Sancar A. Lippard S.J. Biochemistry. 1996; 35: 10004-10013Crossref PubMed Scopus (308) Google Scholar). This model is termed repair shielding. HMGB1, an abundant chromosomal protein in mammalian cells, interacts with platinum-DNA intrastrand d(GpG) and d(ApG) cross-links and interferes with their repair in vitro. It is thus one of the candidate proteins for participation in the repair shielding mechanism (11Huang J.-C. Zamble D.B. Reardon J.T. Lippard S.J. Sancar A. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 10394-10398Crossref PubMed Scopus (340) Google Scholar, 15Pil P.M. Lippard S.J. Science. 1992; 256: 234-237Crossref PubMed Scopus (509) Google Scholar). HMGB1 belongs to the family of proteins that contain at least one HMG box domain, an 80-amino acid DNA-binding motif that recognizes bent DNA structures (16Read C.M. Cary P.D. Crane-Robinson C. Driscoll P.C. Carrillo M.O.M. Norman D.G. Eckstein F. Lilley D.M.J. Nucleic Acids and Molecular Biology. Springer-Verlag, Berlin1995: 222-250Google Scholar, 17Baxevanis A.D. Landsman D. Nucleic Acids Res. 1995; 23: 1604-1613Crossref PubMed Scopus (186) Google Scholar). HMGB1 is highly conserved in mammals with >95% amino acid identity between rodent and human forms (16Read C.M. Cary P.D. Crane-Robinson C. Driscoll P.C. Carrillo M.O.M. Norman D.G. Eckstein F. Lilley D.M.J. Nucleic Acids and Molecular Biology. Springer-Verlag, Berlin1995: 222-250Google Scholar). HMGB1 is an extremely versatile protein. It increases transcription activation involving steroid hormone receptors, p53, Hox, and Pou protein (18Boonyaratanakornkit V. Melvin V. Prendergast P. Altmann M. Ronfani L. Bianchi M.E. Taraseviciene L. Nordeen S.K. Allegretto E.A. Edwards D.P. Mol. Cell. Biol. 1998; 18: 4471-4487Crossref PubMed Scopus (298) Google Scholar, 19Jayaraman L. Moorthy N.C. Murthy K.G.K. Manley J.L. Bustin M. Prives C. Genes Dev. 1998; 12: 462-472Crossref PubMed Scopus (281) Google Scholar, 20Zappavigna V. Falciola L., C.M., H. Mavilio F. Bianchi M.E. EMBO J. 1996; 15: 4981-4991Crossref PubMed Scopus (214) Google Scholar). The regulation of transcription activation by HMGB1 is attributed to its DNA binding and bending activity. Protein-protein interactions between HMGB1 and the transcription factors presumably facilitate the formation of high order nucleoprotein complexes required for transcription initiation (for a review, see Ref. 21Muller S. Scaffidi P. Degryse B. Bonaldi T. Ronfani L. Agresti A. Beltrame M. Bianchi M.E. EMBO J. 2001; 20: 4337-4340Crossref PubMed Scopus (369) Google Scholar). Hmgb1 knockout mice die shortly after birth due to hypoglycemia resulting from a defect in transcription activation by the glucocorticoid receptor (22Calogero S. Grassi F. Aguzzi A. Voigtlander T. Ferrier P. Ferrari S. Bianchi M.E. Nat. Genet. 1999; 22: 276-280Crossref PubMed Scopus (438) Google Scholar). Beside its intranuclear roles, HMGB1 was also discovered recently to function as an extracellular signaling molecule during inflammation, cell differentiation, cell migration, and tumor metastasis (23Scaffidi P. Misteli T. Bianchi M.E. Nature. 2002; 418: 191-195Crossref PubMed Scopus (3247) Google Scholar, 24Wang H. Bloom O. Zhang M. Vishnubhakat J.M. Ombrellino M. Che J. Frazier A. Yang H. Ivanova S. Borovikova L. Manogue K.R. Faist E. Abraham E. Andersson J. Andersson U. Molina P.E. Abumrad N.N. Sama A. Tracey K.J. Science. 1999; 285: 248-251Crossref PubMed Scopus (2890) Google Scholar, 25Taguchi A. Blood D.C. del Toro G. Canet A. Lee D.C., Qu, W. Tanji N., Lu, Y. Lalla E., Fu, C. Hofmann M.A. Kislinger T. Ingram M., Lu, A. Tanaka H. Hori O. Ogawa S. Stern D.M. Schmidt A.M. Nature. 2000; 405: 354-360Crossref PubMed Scopus (1092) Google Scholar). HMGB1 is secreted by certain cells, including macrophages and monocytes (21Muller S. Scaffidi P. Degryse B. Bonaldi T. Ronfani L. Agresti A. Beltrame M. Bianchi M.E. EMBO J. 2001; 20: 4337-4340Crossref PubMed Scopus (369) Google Scholar). The secretion and signaling mechanism by which HMGB1 activates cells during these processes is largely unknown. HMGB1 has been linked to cisplatin activity in a number of studies. HMGB1 binds specifically to cisplatin-modified 1,2-intrastrand d(GpG) and d(ApG) cross-links but not to the DNA adducts formed by the clinically inactive isomer,trans-diamminedichloroplatinum(II) (15Pil P.M. Lippard S.J. Science. 1992; 256: 234-237Crossref PubMed Scopus (509) Google Scholar, 26Hughes E.N. Engelsberg B.N. Billings P.C. J. Biol. Chem. 1992; 267: 13520-13527Abstract Full Text PDF PubMed Google Scholar). Addition of HMGB1 to an in vitro nucleotide excision repair assay inhibited the repair of cisplatin-DNA damage (11Huang J.-C. Zamble D.B. Reardon J.T. Lippard S.J. Sancar A. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 10394-10398Crossref PubMed Scopus (340) Google Scholar, 14Zamble D.B., Mu, D. Reardon J.T. Sancar A. Lippard S.J. Biochemistry. 1996; 35: 10004-10013Crossref PubMed Scopus (308) Google Scholar). Given the abundance of HMGB1 in nuclei, one copy per kb of the human genome, and its roles in various biological processes, it was hypothesized that the cellular HMGB1 level might modulate the cisplatin sensitivity of cancer cells. Consistent with this notion, hormone-induced HMGB1 up-regulation in MCF-7 breast cancer cells correlates with enhanced cisplatin sensitivity (27He Q. Liang C. Lippard S.J. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 5768-5772Crossref PubMed Scopus (199) Google Scholar). Increased cisplatin sensitivity was also observed in a lung adenocarcinoma cell line transfected with a plasmid expressing HMGB2, a protein with more than 80% identity to HMGB1 (28Arioka H. Nishio K. Ishida T. Fukumoto H. Fukuoka K. Nomoto T. Kurokawa H. Yokote H. Abe S. Saijo N. Jpn. J. Cancer Res. 1999; 90: 108-115Crossref PubMed Scopus (23) Google Scholar). A recent study, however, showed that loss of NHP6A, an abundant HMG box protein in Saccharomyces cerevisiae, sensitized yeast to cisplatin, suggesting that a mechanism other than repair shielding was in effect in the yeast system (29Wong B. Masse J.E. Yen Y.M. Giannikopoulos P. Feigon J. Johnson R.C. Giannikoupolous P. Biochemistry. 2002; 41: 5404-5414Crossref PubMed Scopus (36) Google Scholar). To investigate further how HMGB1 might affect cisplatin sensitivity in mammalian cells, we studied the cisplatin sensitivity and cisplatin-induced apoptosis in the mouse Hmgb1−/− cell line. Here, we report the results of this work and discuss its implications. Our studies reveal little difference in the cisplatin sensitivity and cisplatin-induced apoptosis between the Hmgb1−/− and its parental cell lines, suggesting that in this mouse model, HMGB1 does not modulate cellular sensitivity to cisplatin. To our knowledge, this is the first direct examination of the impact of HMGB1 loss on cisplatin sensitivity in mammalian cells. Mouse embryonic fibroblast cell lines, Hmgb1+/+ and Hmgb1−/−, were kindly provided by M. E. Bianchi (22Calogero S. Grassi F. Aguzzi A. Voigtlander T. Ferrier P. Ferrari S. Bianchi M.E. Nat. Genet. 1999; 22: 276-280Crossref PubMed Scopus (438) Google Scholar). Cells were maintained as monolayer cultures in Dulbecco's modified Eagle's media containing 10% heat-inactivated fetal bovine serum and 2 mm l-glutamine at 37 °C in a humidified incubator with 5% CO2. Cell extracts were prepared from near confluent cells on 100-mm plates. Cells were washed with phosphate-buffered saline and lysed in 250 μl of buffer containing 2% SDS, 10 μg/ml of pepstatin, leupeptin and aprotinin, and 0.5 mg/ml Pefabloc in phosphate-buffered saline. The lysate was pulled through a 25G5/8 syringe needle to shear genomic DNA and was cleared by centrifugation. The protein concentrations of extracts were determined by a bicinchoninic acid protein assay kit (Sigma). The proteins in cell extracts were resolved on 12% SDS-PAGE gels and then electroblotted onto polyvinylidene difluoride membranes (Bio-Rad). Following blocking with a 5% bovine serum albumin and 0.01% Tween 20 solution in Tris-buffered saline at pH 7.4, membranes were incubated in the primary antibody, rabbit α-HMGB1 (1:2,000 dilution) (Pharmingen), in 0.01% Tween 20 at pH 7.4 with Tris-buffered saline. Finally, blots were incubated in the secondary antibody, 1:2,000 dilution of α-rabbit whole antibody conjugated to horseradish peroxidase (Amersham Biosciences). After washing, blots were soaked for 1 min in chemiluminescent reagents (Sigma) and then exposed to BioMax film (Eastman Kodak Co.). Cells were seeded on 96-well plates at a density of 1,000 cells/100 μl/well. Treatment with cisplatin began the next day after cells had attached to the plates. For continuous treatment, cells were incubated in growth medium containing various concentrations of cisplatin for 72 h. For short time treatment, cells were treated with cisplatin-containing medium for 4 h followed by incubation in drug-free medium for an additional 90 h. After the cell density of was determined by a The assay was to the 10 μl of in was to of 96-well plates that cells at the of the were incubated growth for and the at was by an of cells were by the of of cultures that of Cisplatin were by the of against the of cisplatin. a of cultures was by sulforhodamine B 10% solution was to the cells. were incubated for min at 4 °C to to to and then washed with were at in the cells in were then with μl of in acid for was by the plates with were was The was by μl of 10 mm to and for min on a The at was by the Cisplatin were as A of cells was on plates and to Cells were then incubated in cisplatin-containing media for h. After the attached cells in were by and with the cells of the Cells were washed with phosphate-buffered saline and in the binding buffer Cell were with a and to a of 1 of cells was with propidium iodide and fluorescein annexin V to the The cell were by a with a Biosciences). The used was for and for were with Cell was from were used to the cisplatin sensitivity of the Hmgb1−/− and wild-type mouse cells. The assay the cell is to a in cells T. J. PubMed Scopus Google Scholar, C. D.M. J. PubMed Scopus Google Scholar). The assay cell density by sulforhodamine B to cells to the plates by S. P. A. J. Natl. Cancer 1990; PubMed Scopus Google Scholar, R.P. Eur. J. Cancer. 1993; Full Text PDF PubMed Scopus Google Scholar). results were by the Cisplatin inhibited the growth of Hmgb1+/+ and to a when to growth medium for 72 h A and a cisplatin treatment followed by an incubation in drug-free medium inhibited the growth of both cell No significant difference between the cisplatin sensitivity of Hmgb1+/+ and Hmgb1−/− cells was observed in A cellular to cisplatin is activation of the pathway A. Cancer 1990; Google Scholar). the study, the apoptosis of Hmgb1+/+ and Hmgb1−/− cells by cisplatin was by with and annexin cells and on the of the work has that in cells with annexin and by K. G. 1996; PubMed Scopus Google Scholar, E. Johnson A. 2000; PubMed Scopus Google Scholar, M. B. 1996; PubMed Scopus Google Scholar). The cells and cells also with in to the annexin V of cell The annexin assay has been to study cisplatin-induced apoptosis in a number of cell K. G. 1996; PubMed Scopus Google Scholar, Mol. 2000; PubMed Scopus Google Scholar, J. 2002; PubMed Scopus Google Scholar). 2 the density of annexin from Hmgb1+/+ and Hmgb1−/− mouse cells. cells were treated with cisplatin for h cell The illustrate cell and by their cells are annexin and cells are annexin and their membranes are not cells are annexin and of cell The and cells are both annexin and The Hmgb1+/+ and Hmgb1−/− cell cultures cells but cells, which we as the cell death in these significant of cells and cells were in The in cultures were than suggesting that cells not from cisplatin The of and cell in cultures treated with various concentrations of cisplatin are in Hmgb1−/− cells of apoptosis as wild-type for concentrations of cisplatin. responses to cisplatin in the Hmgb1−/− and were observed in responses in Hmgb1+/+ and Hmgb1−/− cells. the of of the and cells in the The of HMGB1 are in of the J. PubMed Scopus Google Scholar). It is not have significantly of protein. Here, we used to the of HMGB1 in the mouse fibroblasts with in MCF-7 cells, a human breast cancer line. The of cellular proteins was to SDS-PAGE and the HMGB1 The showed of HMGB1 in the mouse fibroblasts and MCF-7 cells The of this study was to the between HMGB1 and the sensitivity of mammalian cells to cisplatin. We this by the of wild-type cells with of Hmgb1 knockout mouse cells (22Calogero S. Grassi F. Aguzzi A. Voigtlander T. Ferrier P. Ferrari S. Bianchi M.E. Nat. Genet. 1999; 22: 276-280Crossref PubMed Scopus (438) Google Scholar). Hmgb1−/− mice die shortly after birth due to a defect in the activation of the glucocorticoid with the that HMGB1 as a of transcription involving steroid hormone The HMGB1 is also at the cellular The Hmgb1−/− embryonic fibroblasts are in transcription activation by the glucocorticoid and (22Calogero S. Grassi F. Aguzzi A. Voigtlander T. Ferrier P. Ferrari S. Bianchi M.E. Nat. Genet. 1999; 22: 276-280Crossref PubMed Scopus (438) Google Scholar). The Hmgb1−/− cells have a and growth rate to of the Hmgb1+/+ cells, and the of and are in both cell (22Calogero S. Grassi F. Aguzzi A. Voigtlander T. Ferrier P. Ferrari S. Bianchi M.E. Nat. Genet. 1999; 22: 276-280Crossref PubMed Scopus (438) Google Scholar). The Hmgb1−/− and the wild-type cell thus an system for the of HMGB1 in cellular responses to cisplatin. the growth inhibition by cisplatin and cisplatin-induced apoptosis in the Hmgb1−/− and the wild-type cells were that continuous treatment with cisplatin inhibited the growth of Hmgb1−/− cells to the as that of Hmgb1+/+ cells cells were treated with cisplatin for a short time the of both cell were also the cisplatin-induced apoptosis in these cells was by annexin cell cultures of both lines, was a significant but little suggesting that the cells die the pathway cisplatin in the cultures in apoptosis in both cell lines, that apoptosis of the cells was by cisplatin 2 and of the in the Hmgb1−/− and Hmgb1+/+ cultures treated with the concentrations of cisplatin showed the of cell death in both cell these results that the Hmgb1−/− cells are as to cisplatin as the Hmgb1+/+ cells. HMGB1 has been in the cytotoxicity of cisplatin the of its ability to bind cisplatin-modified vitro. A number of Lippard S.J. Biochemistry. 1997; PubMed Scopus Google Scholar, Bianchi M.E. Falciola L. Engelsberg B.N. Billings P.C. and 1996; PubMed Scopus Google Scholar, E.R. Lippard S.J. Biochemistry. 2000; PubMed Scopus Google Scholar, Q. Lippard S.J. Nature. 1999; PubMed Scopus Google Scholar, Whitehead J.P. Lippard S.J. Biochemistry. 1994; PubMed Scopus Google Scholar, C.M. Lippard S.J. Biochemistry. 1995; 34: PubMed Scopus Google have the interactions between HMGB1 and cisplatin-modified DNA. studies, however, the effect of HMGB1 on cisplatin sensitivity at the cellular The results that HMGB1 does not play a significant role in the mechanism of cisplatin-induced cytotoxicity in the mouse embryonic cells. Given the high binding of HMGB1 for cisplatin-modified DNA and the abundance of HMGB1 in mammalian cells, this however, a number of that might HMGB1 from with cisplatin-modified DNA in the cells and modulating their responses to cisplatin. One is that the HMGB1 level in the mouse embryonic fibroblasts is than that of cells in other such as MCF-7 human breast cancer cells, the subject of a study (27He Q. Liang C. Lippard S.J. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 5768-5772Crossref PubMed Scopus (199) Google Scholar). A for HMGB1 in both cell this is that HMGB1 proteins in interactions with other in the cells. HMGB1 HMG and an extremely (21Muller S. Scaffidi P. Degryse B. Bonaldi T. Ronfani L. Agresti A. Beltrame M. Bianchi M.E. EMBO J. 2001; 20: 4337-4340Crossref PubMed Scopus (369) Google Scholar), through which it interacts with other proteins L. Moorthy N.C. Murthy K.G.K. Manley J.L. Bustin M. Prives C. Genes Dev. 1998; 12: 462-472Crossref PubMed Scopus (281) Google Scholar, 20Zappavigna V. Falciola L., C.M., H. Mavilio F. Bianchi M.E. EMBO J. 1996; 15: 4981-4991Crossref PubMed Scopus (214) Google Scholar, M. Bianchi M.E. J. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar). the mouse HMGB1 proteins may in nucleoprotein complexes and may not for binding to cisplatin-modified DNA. A recent study discovered that during apoptosis by tumor HMGB1 attached to the The binding of HMGB1 to may the of HMGB1 to platinum-DNA adducts (23Scaffidi P. Misteli T. Bianchi M.E. Nature. 2002; 418: 191-195Crossref PubMed Scopus (3247) Google Scholar). Finally, as proteins in these embryonic cells may the with cisplatin-modified DNA. A of the between cisplatin sensitivity and protein in cells may to the of such protein our results the importance of cell type in determining the ability of this and other DNA-binding proteins to influence the of cisplatin as a HMGB1 has been to influence cellular sensitivity to cisplatin through binding to cisplatin-DNA 1,2-intrastrand Our results reveal little difference in the cisplatin sensitivity and cisplatin-induced apoptosis in embryonic and Hmgb1−/− cell lines, suggesting that in this mouse model, HMGB1 does not modulate the cellular sensitivity to cisplatin.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: